Retrospective Real-word Study of Linezolid for the Treatment of Tuberculous Meningitis
Launched by HUASHAN HOSPITAL · Mar 29, 2019
Trial Information
Current as of May 27, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • all patients diagnosed as TBM from the electronic medical record system.
- Exclusion Criteria:
- • Does not meet the established diagnostic criteria;
- • Combine other pathogen central infections;
- • Follow-up confirmed that the final diagnosis considers other diseases (such as tumors, autoimmune encephalitis, etc.);
- • Our hospital has less than one week of anti-tuberculosis treatment;
- • Lack of information
About Huashan Hospital
Huashan Hospital, affiliated with Fudan University in Shanghai, is a leading medical institution renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, Huashan Hospital leverages its extensive expertise in various medical disciplines to advance the development of new therapies and treatment modalities. The hospital's state-of-the-art facilities and multidisciplinary teams facilitate rigorous clinical investigations, ensuring adherence to ethical standards and regulatory compliance. With a focus on improving patient outcomes, Huashan Hospital actively collaborates with academic and industry partners to drive forward-thinking research initiatives that address critical healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials